Patients' characteristics and response to Hsp32/HO-1-targeted drugs
| Patient no. . | Sex . | Age, y . | CML phase . | Imatinib-resistant . | WBC, G/L . | Hb g/dL . | Plt, G/L . | Cytogenetics . | BCR/ABL point mutations . | IC50 SMA-ZnPP . | IC50 PEG-ZnPP . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 47 | BP | Yes | 30.4 | 10.6 | 141 | t(9;22), i17, +8 | Glu279/Lys His396/Arg | 5 | n.t. |
| 2 | F | 46 | CP | No | 38.8 | 11.9 | 569 | t(9;22) | wt | 10 | n.t. |
| 3 | M | 49 | BP | No | 16.58 | 12.2 | 871 | t(9;22) | wt | 15 | n.t. |
| 4 | M | 59 | CP | No | 159.4 | 12.4 | 168 | t(9;22) | n.t. | 3 | n.t. |
| 5 | F | 80 | CP | No | 17.1 | 13.7 | 247 | t(9;22) | n.t. | n.t. | 2 |
| 6 | M | 67 | AP | Yes | 49.5 | 14.1 | 638 | t(9;22) | Glu255Lys | n.t. | 4 |
| 7 | M | 69 | AP | Yes | 19.1 | 8.4 | 132 | t(9;22) | wt | n.t. | 4 |
| 8 | F | 67 | CP | No | 27.9 | 13.2 | 178 | t(9;22) | wt | n.t. | 10 |
| 9 | M | 18 | AP | No | 37 | 11.8 | 114 | t(9;22), +8 | n.t. | n.t. | 13 |
| 10 | M | 66 | BP | Yes | 3.4 | 7.5 | 121 | t(9;22), i17, +8 | Val379Ile | n.t. | 20 |
| 11 | M | 74 | CP | No | 13.7 | 8.7 | 720 | t(9;22) | wt | n.t. | 6 |
| 12 | F | 58 | CP | No | 28.9 | 13.5 | 347 | t(9;22) | n.t. | n.t. | 3 |
| 13 | M | 65 | BP | Yes | 96.1 | 11.3 | 66 | t(9;22) | Thr315Ala Gly250Glu | 15 | 10 |
| 14 | M | 30 | CP | No | 156.8 | 12.2 | 171 | t(9;22) | wt | n.t. | 12 |
| 15 | M | 64 | CP | No | 342 | 8.9 | 478 | t(9;22) | n.t. | 7 | n.t. |
| 16 | F | 74 | CP | No | 103.5 | 10.5 | 717 | t(9;22) | n.t. | 5 | n.t. |
| 17 | M | 19 | CP | No | 96 | 14.6 | 500 | t(9;22) | n.t. | 6 | 18 |
| 18 | F | 45 | CP | No | 89.1 | 12.2 | 536 | t(9;22) | n.t. | n.t. | 12 |
| 19 | M | 73 | AP | No | 112.2 | 11.9 | 394 | t(9;22), t(2;10) | n.t. | 8 | n.t. |
| 20 | M | 68 | CP | No | 190.0 | 12.3 | 490 | t(9;22) | n.t. | 8 | n.t. |
| 21 | M | 67 | CP | No | 41.4 | 14.8 | 310 | t(9;22) | n.t. | 8 | 20 |
| 22 | M | 73 | CP | Yes | 21.1 | 13.7 | 754 | t(9;22) | Phe359Val | n.t. | 12 |
| 23 | M | 67 | AP | Yes | 16.2 | 9.9 | 69 | t(9;22) | Met244Val | 6 | 8 |
| Patient no. . | Sex . | Age, y . | CML phase . | Imatinib-resistant . | WBC, G/L . | Hb g/dL . | Plt, G/L . | Cytogenetics . | BCR/ABL point mutations . | IC50 SMA-ZnPP . | IC50 PEG-ZnPP . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 47 | BP | Yes | 30.4 | 10.6 | 141 | t(9;22), i17, +8 | Glu279/Lys His396/Arg | 5 | n.t. |
| 2 | F | 46 | CP | No | 38.8 | 11.9 | 569 | t(9;22) | wt | 10 | n.t. |
| 3 | M | 49 | BP | No | 16.58 | 12.2 | 871 | t(9;22) | wt | 15 | n.t. |
| 4 | M | 59 | CP | No | 159.4 | 12.4 | 168 | t(9;22) | n.t. | 3 | n.t. |
| 5 | F | 80 | CP | No | 17.1 | 13.7 | 247 | t(9;22) | n.t. | n.t. | 2 |
| 6 | M | 67 | AP | Yes | 49.5 | 14.1 | 638 | t(9;22) | Glu255Lys | n.t. | 4 |
| 7 | M | 69 | AP | Yes | 19.1 | 8.4 | 132 | t(9;22) | wt | n.t. | 4 |
| 8 | F | 67 | CP | No | 27.9 | 13.2 | 178 | t(9;22) | wt | n.t. | 10 |
| 9 | M | 18 | AP | No | 37 | 11.8 | 114 | t(9;22), +8 | n.t. | n.t. | 13 |
| 10 | M | 66 | BP | Yes | 3.4 | 7.5 | 121 | t(9;22), i17, +8 | Val379Ile | n.t. | 20 |
| 11 | M | 74 | CP | No | 13.7 | 8.7 | 720 | t(9;22) | wt | n.t. | 6 |
| 12 | F | 58 | CP | No | 28.9 | 13.5 | 347 | t(9;22) | n.t. | n.t. | 3 |
| 13 | M | 65 | BP | Yes | 96.1 | 11.3 | 66 | t(9;22) | Thr315Ala Gly250Glu | 15 | 10 |
| 14 | M | 30 | CP | No | 156.8 | 12.2 | 171 | t(9;22) | wt | n.t. | 12 |
| 15 | M | 64 | CP | No | 342 | 8.9 | 478 | t(9;22) | n.t. | 7 | n.t. |
| 16 | F | 74 | CP | No | 103.5 | 10.5 | 717 | t(9;22) | n.t. | 5 | n.t. |
| 17 | M | 19 | CP | No | 96 | 14.6 | 500 | t(9;22) | n.t. | 6 | 18 |
| 18 | F | 45 | CP | No | 89.1 | 12.2 | 536 | t(9;22) | n.t. | n.t. | 12 |
| 19 | M | 73 | AP | No | 112.2 | 11.9 | 394 | t(9;22), t(2;10) | n.t. | 8 | n.t. |
| 20 | M | 68 | CP | No | 190.0 | 12.3 | 490 | t(9;22) | n.t. | 8 | n.t. |
| 21 | M | 67 | CP | No | 41.4 | 14.8 | 310 | t(9;22) | n.t. | 8 | 20 |
| 22 | M | 73 | CP | Yes | 21.1 | 13.7 | 754 | t(9;22) | Phe359Val | n.t. | 12 |
| 23 | M | 67 | AP | Yes | 16.2 | 9.9 | 69 | t(9;22) | Met244Val | 6 | 8 |
CP indicates chronic phase; AP, accelerated phase; BP, blast phase; WBC, white blood cell count; Hb, hemoglobin; Plt, platelet count; wt, wild type BCR/ABL; and n.t., not tested.